Tanabe Mitsubishi Files For Approval Of Telavic For Genotype 2 Hepatitis C In Japan
This article was originally published in PharmAsia News
Executive Summary
Tanabe Mitsubishi has filed an application for the approval of Telavic (telaprevir) for the treatment of genotype 2 chronic hepatitis C in Japan.